From Anatomy to Biology: Tumor Location has Limited Independent Value in Predicting Pathological Complete Response After Neoadjuvant Chemoradiotherapy.

Authors

Omer Akay, Abdullah Gunes, Mert Guler, Ibrahim Unlu, Murat Burc Yazicioglu, Feyyaz Adasiroglu, Husnu Ozan Sevik, Ozan Can Tatar, Ufuk Oguz Idiz

Published in

The American surgeon. Pages 31348261497817. Oct 11, 2026. Epub Oct 11, 2026.

Abstract

BackgroundNeoadjuvant therapy is the standard treatment for locally advanced rectal cancer; however, treatment response remains heterogeneous, and research has increasingly shifted from isolated anatomical predictors toward biologically integrated response assessment. This study evaluated whether anatomical tumor location was independently associated with pathological response to neoadjuvant therapy.Materials and MethodsThis multicenter retrospective study included 179 patients with stages II-III rectal adenocarcinoma undergoing long-course neoadjuvant chemoradiotherapy followed by total mesorectal excision between January 2023 and January 2026. Tumor location was categorized as upper (>10 cm), mid (5-10 cm), or low (<5 cm) rectum. Pathological response was assessed using the modified Ryan system, and major response was defined as TRG 0-1. Multivariable binary logistic regression evaluated factors associated with major pathological response, with multinomial regression as a secondary exploratory analysis.ResultsIn the primary multivariable analysis, tumor location was not independently associated with major pathological response (global P = .358). Major response occurred in 47.5% of patients without lymphovascular invasion but in only 3.3% of those with lymphovascular invasion, which was associated with lower odds of major response (OR 0.05, 95% CI 0.01-0.15; P < .001).ConclusionAnatomical tumor location was not independently associated with pathological response following neoadjuvant chemoradiotherapy. These findings suggest that response assessment should extend beyond simple anatomical variables and be interpreted within the broader context of tumor biology and integrated clinicopathological assessment.

PMID:
42859999
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.